Next Phase Newsletter

An early stage VC founded by a group of alumni from a leading university is based in the US. The group currently has $100M, under management. The group focuses on Angel to Series B stage companies across various sectors, including pharmaceutical, medical device, services and tools, and digital health. The typical investment size is between $1M to $2M. The group also syndicates with other investors for larger investments. The firm looks to make investments across the globe. 
 
The firm is currently looking for new opportunities in the life science space. The fund is opportunistic in terms of sectors, subsectors and indications. The fund typically invests in seed rounds and series A rounds. Historically, the fund has been active in life science companies developing innovative platform technologies and cross-disciplinary technologies. 
 
The firm focuses on investments in private companies and typically invests in pre-clinical and early clinical stage companies with strong and experienced management teams. The firm will take a board seat or observer seat occasionally, depending on the investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A Private Equity firm with multiple offices throughout the US is currently making investments out of its latest fund of over $700M. The firm looks to make multi-stage investments ranging from $20-$50 million. The firm is willing to review opportunities from around the Globe with a heavy emphasis on North America. 
 
The firm is currently interested broadly in the healthcare space including Medical Technology, Therapeutics, Diagnostics, Laboratory Equipment, Healthcare IT and R&D services. For medical technology the firm is looking for companies that have at least an alpha prototype and have some efficacy data. For companies working with therapeutics the firm is looking for assets that are in Phase II of clinical trials and will only consider companies in Phase I if they have efficacy data. The firm generally does not look for companies in the cardiovascular space and they are open to orphan indications. The firm is also open to investing in companies that have products already on the market. 
 
The firm looks for a strong management team to be in place and is open to invest in both private and publicly held companies. For companies that are privately held the firm generally looks to take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A corporate venture of a publicly listed pharmaceutical group in Taiwan has successfully invested and established 7 IPO companies in Taiwan and Hong Kong.  The firm now focuses on strategic investments which can synergize with its portfolio companies or future business. The firm is open to consider investment opportunities globally, and is willing to help overseas portfolio companies enter into Asia through licensing or joint venture activities.  Typical allocation size can range from US$3-20 million. 
 
The firm is investing strategically in selected sectors. Within therapeutics, the firm considers in companies with technology platforms in cell therapy, RNA therapies, bispecific and ADC drugs.  Investment stage can range from preclinical to early clinical stage.  The firm is also interested in investing in early stage CDMO companies in the areas above. 
 
The firm is looking for experienced management teams with proven track records. The firm typically requests a board seat in its portfolio company. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A group founded by Chinese medical device experts, based in Suzhou, China, seeks to allocate 5-20 Million RMB (0.7-3 Million USD) in various early stage life science opportunities. The firm seeks to make several investments in the upcoming year and focusing on opportunities raising angel,  pre-A, Series A, and B rounds. The firm seeks to make use of their founders’ expertise and successes in the medical device industry to help guide their investments towards growth and success. The firm is investing out of a CNY fund and as a result, is currently focused on companies willing to start a joint venture in China. 
 
The firm is primarily interested in medical devices and in vitro diagnostic (IVD) technologies and/or companies. More specifically, they’re interested in opportunities in areas related to cardiology, neuromodulation, in vitro diagnostics, and imaging as that is where they have the most expertise. However, they are willing to look at other areas as well so long as the opportunity is interesting and has the potential to be developed. The firm is also interested in investing in R&D services as well. The firm’s most recent investment was in a company that utilized AI to process images in order for better and faster diagnoses. 
 
The firm heavily prefers that the company has a China angle to work with. They believe that they can contribute more to companies who wish to work in China through connections they have already made such as through helping acquire non-dilutive funds from the government of China and utilizing various connections in industrial parks across China. The firm also wishes to work with companies that are willing to work with the partners at the firm so that they can utilize their prior experiences to help the companies grow. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
 

A venture capital firm headquartered in the US is actively investing in the intersection of science, technology, and neurology, and has invested in over 30 companies to date. The firm invests primarily in Seed to Series A rounds. While the firm has mostly invested in USA-based companies, the firm is open to opportunities beyond. 
 
Within life sciences, the firm is interested in drug development and drug development-enabling tools and technologies, medical devices with a software component, and wearables. Relating to therapeutics, the firm is particularly interested in psychedelics and plant-based therapies. The firm is most interested in technologies that target mental & behavioral health and CNS/neurodegenerative disease. The firm is open to early-stage, pre-clinical companies. 
 
The firm has no specific company or management team requirements, and is open to acting as either lead or co-investor, seeking board representation when leading rounds. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A sector-exclusive life sciences venture and growth equity fund is focused on Asia, particularly China. The firm has offices in China, Hong Kong, and the US. The firm has multiple billion AUM, is stage agnostic, investing as early as seed, growth, and up to pre-IPO opportunities. The firm has a team of investment professionals all with healthcare background. Investment size is USD $5-25 million per company. The firm prefers to lead or co-lead a financing round. With both USD and RMB funds, the firm focuses on China but also considers opportunities from USA.In life sciences, the firm is focused on therapeutics with an emphasis on oncology, metabolic disorders, cell therapy, and biologics, etc. The firm is also interested in medical devices and diagnostics. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA.

The firm is seeking experienced management teams that are going rapidly and emerging as market leaders.  The firm is seeking companies developing technologies that are truly based on high quality science, but also aligned with the potential of attractive financial return. Because the firm focuses its activities in China, the firm will prefer companies outside of China to have a strong China angle. The firm typically requires a board seat or observation rights post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

An investment fund located in Western Europe focuses on early-stage life science investments, more specifically in drug development, medical devices, and diagnostics. The fund makes Pre-Seed, Seed, and Series A investments with an investment sweet spot of around €1.5 M. The maximum investment in one project can be €5.3 M in several rounds, preferentially in equity investments. The firm is led by an experienced team of professionals with backgrounds in private equity, the healthcare industry, and venture capital, who can support entrepreneurs on their journey to global success. Thanks to close cooperation with the fund’s main sponsor, a leading biotech incubator, the firm has a great opportunity to be at the origin of transformative Central European technologies.

The firm is seeking opportunities in drug development, medical devices, diagnostics, and other life sciences. The firm is agnostic to subsectors and indications, and expects to see some pre-clinical data (ideally in vivo PoC) from the start-up companies, to consider investment.

The firm is open to all types of management teams. The firm can lead the investment round under specific circumstances, or co-invest and will seek a board seat when leading. The firm prefers to syndicate for all of their investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.